Upgrade to SI Premium - Free Trial

Form SCHEDULE 13D/A Adagene Inc. Filed by: Luo Peter

June 8, 2026 6:23 AM





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
Row 7 and 11 represent (i) 149,514 ordinary shares (including ordinary shares represented by the ADSs) held by Peter Luo; (ii) 2,081,484 ordinary shares underlying share options granted to Peter Luo that are vested or will be vested within 60 days of June 05, 2026, (iii) 56,021 ordinary shares (including ordinary shares represented by the ADSs) held by Xiaohong She; (iv) 378,227 ordinary shares underlying share options granted to Xiaohong She that are vested or will be vested within 60 days of June 05, 2026, (v) total of 1,851,500 ordinary shares (including ordinary shares represented by the ADSs) held by Raymond Tam, Qinghai Zhao and several key employees of the Company, and (vi) total of 1,726,252 share options granted to Raymond Tam, Qinghai Zhao and several key employees that are vested or will be vested within 60 days of June 05, 2026. Row 9 represents (i) 149,514 ordinary shares (including ordinary shares represented by the ADSs) held by Peter Luo; and (ii) 2,081,484 ordinary shares underlying share options granted to Peter Luo that are vested or will be vested within 60 days of June 05, 2026. Row 10 represents (i) 56,021 ordinary shares held by Xiaohong She (including ordinary shares represented by the ADSs); and (ii) 378,227 ordinary shares underlying share options granted to Xiaohong She that are vested or will be vested within 60 days of June 05, 2026. Row 13 represents calculation based on (i) 83,832,157 ordinary shares issued and outstanding as of May 31, 2026, as provided by the Issuer and (ii) 4,185,963 ordinary shares underlying share options granted to Peter Luo-Acting-in-Concert-Group that are vested or will be vested within 60 days of June 05, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
Rows 7, 9 and 11 represents 9,390,439 ordinary shares held by HAN 2020 Irrevocable Trust. The HAN 2020 Irrevocable Trust is a family trust established by Dr. Peter Luo as trustor for the benefits of Dr. Luo's family members, of which North Point Trust Company is the current trustee. Row 13 represents calculation based on 83,832,157 ordinary shares issued and outstanding as of May 31, 2026, as provided by the Issuer.


SCHEDULE 13D


Peter Luo
Signature:/s/ Peter Luo
Name/Title:Peter Luo
Date:06/08/2026
HAN 2020 Irrevocable Trust
Signature:/s/ Todd Wiles
Name/Title:North Point Trust Company/ Trustee
Date:06/08/2026

Categories

SEC Filings